Disruption of protein translation in FXS mouse models led to evaluation of the therapeutic potential of modulation of neurotransmitter receptor activity that regulates translation of proteins critical for synaptic plasticity, such as group 1 metabotropic glutamate receptor (mGluR1 and mGluR5) activity (4). Here, GRM5 is linked to fragile X syndrome.